Overview

Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint

Status:
Terminated

Trial end date:
2009-04-01

Target enrollment:

Participant gender:

Summary

This is a phase II, multi-center, open-label, single-arm clinical trial to be conducted in the United States. In approximately 55 centers, approximately 75 eligible locally advanced unresectable or metastatic pancreatic cancer subjects will be enrolled to receive first-line therapy of gemcitabine and panitumumab.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen

Treatments:

Antibodies, Monoclonal
Gemcitabine
Pancrelipase
Panitumumab